In the Claims:

Please amend the claims as follows pursuant to format proposed for revision of 37 C.F.R. §1.121. Unamended pending claims are reproduced below and identified as (original), (currently amended), (previously added, currently amended) or (new).

1. (currently amended) A method of treating prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor more effectively than monoclonal antibody ~~4D5~~.

2. (original) The method of claim 1 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.

3. (original) The method of claim 1 wherein the antibody blocks TGF-α activation of mitogen-activated protein kinase (MAPK).

B1

4. (currently amended) The method of claim 1 wherein the antibody blocks formation of an ErbB hetero-oligomer ~~has a biological characteristic of monoclonal antibody 2C4~~.

5. (currently amended) The method of claim ~~4~~ 1 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.

6. (original) The method of claim 1 wherein the antibody is an antibody fragment.

7. (original) The method of claim 6 wherein the antibody fragment is a Fab fragment.

8. (original) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

9. (original) The method of claim 6 wherein the antibody fragment is not conjugated with a cytotoxic agent.

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

B1

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (previously added, currently amended) A method of treating prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody ~~having biological characteristics of monoclonal antibody 2C4, whereby the antibody~~ which binds

ErbB2, blocks ligand activation of an ErbB receptor, blocks binding of monoclonal antibody 2C4 to ErbB2, and blocks TGF-α activation of mitogen-activated protein kinase (MAPK).

23. (previously added) The method of claim 22 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.

24. (previously added) The method of claim 22 wherein the antibody is an antibody fragment.

25. (previously added) The method of claim 24 wherein the antibody fragment is a Fab fragment.

B1

26. (previously added) The method of claim 22 wherein the antibody is not conjugated with a cytotoxic agent.

27. (previously added) The method of claim 24 wherein the antibody fragment is not conjugated with a cytotoxic agent.

28. (previously added, currently amended) A method of treating androgen dependent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which ~~has biological characteristics of~~ binds to an ErbB2 epitope bound by monoclonal antibody 2C4.

29. (previously added) The method of claim 28 which results in an increased prostate specific antigen (PSA) index in the human.

30. (previously added) The method of claim 28 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.

Please add the following claim:

31. (new) A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor more effectively than monoclonal antibody 4D5.

In the Application:

Please amend the application to delete David B. Agus and Howard I. Scher as inventors of the application.